nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.08.2016 | Original Article – Clinical Oncology

Analysis of the clinicopathologic characteristics and prognostic of stage I invasive mucinous adenocarcinoma

verfasst von: Jizhuang Luo, Rui Wang, Baohui Han, Jie Zhang, Heng Zhao, Wentao Fang, Qingquan Luo, Jun Yang, Yunhai Yang, Lei Zhu, Tianxiang Chen, Xinghua Cheng, Qingyuan Huang, Yiyang Wang, Jiajie Zheng, Haiquan Chen

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The correlations between histological, clinical features and prognosis of stage I invasive mucinous adenocarcinoma (IMA) have not been thoroughly studied for its rare incidence. This study aimed to compare the prognosis among IMA with different percentage of mucinous component and the effect of adjuvant chemotherapy on IMA patients.

Methods

A total of 145 stage I IMA and 3536 invasive nonmucinous adenocarcinoma patients with R0 resection were included. Based on the percentage of mucinous pattern presented in tumor, IMA were classified into two subgroups: pure mucinous (>90 % invasive mucinous pattern) and mixed mucinous/nonmucinous (≥10 % of each histologic component). Invasive nonmucinous adenocarcinomas were classified into three subgroups: lepidic (LEP), acinar/papillary (ACN/PAP) and solid/micropapillary (SOL/MIP). Disease-free survival (DFS) and overall survival (OS) were assessed and compared among IMA and invasive nonmucinous patients.

Results

For IMA patients, DFS (p = 0.003) was worse for mixed mucinous/nonmucinous compared with pure mucinous subgroup, OS (p = 0.514) was not prognostically different between two groups. There were no significant difference for DFS (p = 0.428) and OS (p = 0.232) between IMA and invasive nonmucinous adenocarcinoma. However, statistical significance were seen for DFS (p < 0.001) and OS (p < 0.001) between 5 major histological subgroups: LEP and pure IMA showed excellent prognosis, mixed mucinous/nonmucinous IMA and SOL/MIP subtypes presented the worst prognosis. No significant survival benefit from adjuvant chemotherapy for IMA patients.

Conclusions

Mixed mucinous/nonmucinous IMA had a worse DFS compared with pure mucinous. Early stage IMA could not benefit from adjuvant chemotherapy.

Bueno R et al (2015) Validation of a molecular and pathological model for five-year mortality risk in patients with early stage lung adenocarcinoma. J Thorac Oncol 10:67–73. doi:10.1097/JTO.0000000000000365 CrossRefPubMed

Cai D et al (2014) Comparison of clinical features, molecular alterations, and prognosis in morphological subgroups of lung invasive mucinous adenocarcinoma. OncoTargets therapy 7:2127–2132. doi:10.2147/OTT.S70984 PubMedPubMedCentral

Coutinho D, Goncalves A, Antunes A, Campainha S, Miranda J, Barroso A (2016) Adjuvant chemotherapy in stage IB non-small cell lung carcinoma: a survival analysis. Revista Port de Pneumol 22:123–125. doi:10.1016/j.rppnen.2015.09.005

Eberhard DA et al (2005) Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23:5900–5909. doi:10.1200/JCO.2005.02.857 CrossRefPubMed

Ettinger DS et al (2015) Non-Small Cell Lung Cancer, Version 6.2015. J Natl Compr Cancer Netw 13:515–524

Goldstraw P et al (2007) The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2:706–714. doi:10.1097/JTO.0b013e31812f3c1a CrossRefPubMed

Hata A et al (2010) Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma. J Thorac Oncol 5:1197–1200. doi:10.1097/JTO.0b013e3181e2a2bc CrossRefPubMed

He J et al (2015) Adjuvant chemotherapy for the completely resected stage ib nonsmall cell lung cancer: a systematic review and meta-analysis. Medicine 94:e903. doi:10.1097/MD.0000000000000903 CrossRefPubMedPubMedCentral

Hung JJ, Wu YC, Chou TY, Jeng WJ, Yeh YC, Hsu WH (2016) Adjuvant chemotherapy improves the probability of freedom from recurrence in patients with resected stage IB Lung Adenocarcinoma. Ann Thorac Surg 101:1346–1353. doi:10.1016/j.athoracsur.2015.10.075 CrossRefPubMed

Ichinokawa H et al (2013) Distinct clinicopathologic characteristics of lung mucinous adenocarcinoma with KRAS mutation. Hum Pathol 44:2636–2642. doi:10.1016/j.humpath.2013.05.026 CrossRefPubMed

Kadota K et al (2014) Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation. Am J Surg Pathol 38:1118–1127. doi:10.1097/PAS.0000000000000246 CrossRefPubMedPubMedCentral

Lee HY et al (2016) Prognosis in resected invasive mucinous adenocarcinomas of the lung: related factors and comparison with resected nonmucinous adenocarcinomas. J Thorac Oncol. doi:10.1016/j.jtho.2016.03.011

Marabese M et al (2015) KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy Oncotarget 6:34014–34022. doi:10.18632/oncotarget.5607 PubMed

Massarelli E et al (2007) KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 13:2890–2896. doi:10.1158/1078-0432.CCR-06-3043 CrossRefPubMed

Pan W, Yang Y, Zhu H, Zhang Y, Zhou R, Sun X (2016) KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies. Oncotarget 7:8373–8388. doi:10.18632/oncotarget.7080 PubMedPubMedCentral

Park SY et al (2013) Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer. J Cardiothorac Surg 8:151. doi:10.1186/1749-8090-8-151 CrossRefPubMedPubMedCentral

Qu Y et al (2016) Prognostic analysis of primary mucin-producing adenocarcinoma of the lung: a comprehensive retrospective study. Tumour Biol 37:887–896. doi:10.1007/s13277-015-3869-1 CrossRefPubMed

Russell PA, Wainer Z, Wright GM, Daniels M, Conron M, Williams RA (2011) Does lung adenocarcinoma subtype predict patient survival? A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol 6:1496–1504. doi:10.1097/JTO.0b013e318221f701 CrossRefPubMed

Shim HS et al (2015) Unique genetic and survival characteristics of invasive mucinous adenocarcinoma of the lung. J Thorac Oncol 10:1156–1162. doi:10.1097/JTO.0000000000000579 CrossRefPubMed

Travis WD et al (2011) International association for the study of lung cancer/American Thoracic Society/European Respiratory Society International multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6:244–285. doi:10.1097/JTO.0b013e318206a221 CrossRefPubMedPubMedCentral

Truini A et al (2015) Classification of different patterns of pulmonary adenocarcinomas. Expert Rev Respir Med 9:571–586. doi:10.1586/17476348.2015.1083428 CrossRefPubMed

Tsao MS et al (2015) Subtype classification of lung adenocarcinoma predicts benefit from adjuvant chemotherapy in patients undergoing complete resection. J Clin Oncol 33:3439–3446. doi:10.1200/JCO.2014.58.8335 CrossRefPubMed

Warth A et al (2012) The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol 30:1438–1446. doi:10.1200/JCO.2011.37.2185 CrossRefPubMed

Yanagawa N, Shiono S, Abiko M, Ogata SY, Sato T, Tamura G (2013) New IASLC/ATS/ERS classification and invasive tumor size are predictive of disease recurrence in stage I lung adenocarcinoma. J Thorac Oncol 8:612–618. doi:10.1097/JTO.0b013e318287c3eb CrossRefPubMed

Zhang Y et al (2014) The prognostic and predictive value of solid subtype in invasive lung adenocarcinoma. Sci Rep 4:7163. doi:10.1038/srep07163 CrossRefPubMedPubMedCentral

Zheng D et al (2016) The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations. OncoTargets Therapy 9:833–843. doi:10.2147/OTT.S96834 CrossRefPubMedPubMedCentral

Titel: Analysis of the clinicopathologic characteristics and prognostic of stage I invasive mucinous adenocarcinoma
verfasst von: Jizhuang Luo
Rui Wang
Baohui Han
Jie Zhang
Heng Zhao
Wentao Fang
Qingquan Luo
Jun Yang
Yunhai Yang
Lei Zhu
Tianxiang Chen
Xinghua Cheng
Qingyuan Huang
Yiyang Wang
Jiajie Zheng
Haiquan Chen
Publikationsdatum: 01.08.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 8/2016
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-016-2201-9

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Analysis of the clinicopathologic characteristics and prognostic of stage I invasive mucinous adenocarcinoma

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2016

High-risk and low-risk gastric cancer areas in Italy and its association with microsatellite instability

Low molecular weight heparin and cancer survival: clinical trials and experimental mechanisms

Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer

Endometrial and cervical cancer patients with multiple sentinel lymph nodes at laparoscopic ICG mapping: How many are enough?

Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer

Prognostic and predictive miRNA biomarkers in bladder, kidney and prostate cancer: Where do we stand in biomarker development?

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie